New cocktail of drugs aims to tackle tough colorectal cancer
NCT ID NCT07106034
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial is testing whether adding two immune-boosting drugs (ongericimab and toripalimab) to standard second-line chemotherapy can shrink tumors in people with advanced MSS/pMMR colorectal cancer. The study enrolls 32 adults whose cancer progressed after first-line treatment. Participants receive one of two chemotherapy regimens depending on their prior treatment, plus the two study drugs and bevacizumab. The main goal is to see how many patients respond, with secondary goals including how long the response lasts and overall survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ongericimab, toripalimab, bevacizumab, and chemotherapy (FOLFOX or FOLFIRI)
What this could lead to
If successful, this could offer a new second-line treatment option for people with a hard-to-treat form of colorectal cancer that has stopped responding to initial therapy.
What could go wrong
This is a small, early-phase trial with only 32 participants and no comparison group, so results may not apply broadly. The combination of multiple drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Pudong Hospital
RECRUITINGShanghai, Shanghai Municipality, 201399, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact